Search

Your search keyword '"Borden, E."' showing total 519 results
Start Over Author "Borden, E."
519 results on '"Borden, E."'

16. A national drug agency

Author

West, Roy, Borden, E. Keith, Collet, Jean-Paul, Rawson, Nigel S.B., and Tonks, Robert S.

Published
2003

29. Phase II SWOG-directed Intergroup Trial (S0505) of Sorafenib in Advanced Soft Tissue Sarcomas

Author

von Mehren, M., Rankin, C., Goldblum, J.R., Demetri, G.D., Bramwell, V., Ryan, C.W., and Borden, E.

Subjects
Adult, Aged, 80 and over, Leiomyosarcoma, Male, Niacinamide, Pyridines, Phenylurea Compounds, Benzenesulfonates, Antineoplastic Agents, Sarcoma, Liposarcoma, Middle Aged, Sorafenib, Prognosis, Article, Vascular Neoplasms, Survival Rate, Humans, Female, Aged
Abstract

Patients with advanced soft tissue sarcomas (STS) have limited therapeutic options. Sorafenib (BAY 43-9006) is a multitargeted tyrosine kinase inhibitor of raf, vascular endothelial growth factor receptors 1 (VEGFR1) through 3, platelet-derived growth factor B, fms-like tyrosine kinase 3, and c-kit, and some of these may be relevant in STS.The authors tested sorafenib at a dose of 400 mg twice daily in patients with advanced vascular sarcoma (VS), high-grade liposarcomas, and leiomyosarcomas who had received 0 or 1 previous regimens for advanced disease.Fifty-one patients were accrued to the study, and 37 were evaluable for toxicity and response. There were no unexpected side effects and no confirmed responses. The median progression-free survival was 3 months, and the median overall survival was 17 months. Six of 8 patients in the VS cohort had prolonged clinical benefit (stable disease or better), resulting in a median progression-free survival of 5 months compared with 2 to 3 months for the patients who had liposarcoma and leiomyosarcomas.Sorafenib at the dose and schedule studied did not result in any responses in the VS, liposarcoma, or leiomyosarcoma cohort according to Response Evaluation Criteria in Solid Tumors.

Published
2011

30. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, B.A., Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A., Coukos, G., Gruijl, T.D. de, Dillman, R.O., and Dolstra, H.

Subjects
Immune Regulation Translational research [NCMLS 2], GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Contains fulltext : 97787.pdf (Publisher’s version ) (Open Access)

Published
2011

31. Circulating Tumor Cells (CTCs) in Advanced Lung Cancer: Prognostic Impact of Quantification and Morphology by 2 Separate Techniques

Author

Hashemi Sadraei, N., primary, Williams, A., additional, Du, L., additional, Pennell, N., additional, Ma, P., additional, Jacobs, B., additional, Ao, Z., additional, Rawal, S., additional, McConnell, M., additional, Haddad, A., additional, Spiro, T., additional, Jia, X., additional, Elson, P., additional, Datar, R., additional, Cote, R., additional, and Borden, E., additional

Published
2014
Full Text
View/download PDF

33. Soft tissue sarcomas of adults: state of the translational science

Author

Borden, E. C., Baker, L. H., Bell, R. S., Bramwell, V., Demetri, G. D., Eisenberg, B. L., Fletcher, C. D. M., Fletcher, J. A., Ladanyi, M., Meltzer, P., O Sullivan, B., Parkinson, D. R., Pisters, P. W. T., Saxman, S., Samuel Singer, Sundaram, M., Oosterom, A. T., Verweij, J., Waalen, J., Weiss, S. W., and Brennan, M. F.

Subjects
Adult, Chromosome Aberrations, Chemotherapy, Adjuvant, Karyotyping, Humans, Sarcoma, Retroperitoneal Neoplasms, Oligonucleotide Array Sequence Analysis
Abstract

Sarcomas--like leukemias, which are also mesodermal malignancies--carry biological significance disproportionate to their clinical frequency. Identification of mutations and translocations associated with these tumors has illuminated aberrant signaling pathways that cause these diseases, determine their behavior, and are therapeutic targets. Activated receptor-associated tyrosine kinase c-kit, mutated in most gastrointestinal stromal tumors, has proven a clinically effective target for enzyme inhibition. A translocation involving a single gene family, consisting of EWS and related genes, has been identified in five different sarcomas, and its chimeric protein products could prove similarly amenable to inhibitors. Resolution of the histopathological complexity is being aided by data from molecular and chromosomal characterization. Improvements in imaging, definition of prognostic factors, and surgical and radiotherapeutic treatment have resulted in improved local control. Continued progress will depend on further adapting the rapidly evolving technologies of genomics and proteomics. It will also depend upon accurate histopathological diagnosis based on validated reagents and consistent methodologies applied to adequate tissue samples derived from patients with complete clinical data. Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality.

Published
2003

34. Defining the Critical Hurdles in Cancer Immunotherapy

Author

Fox, BA, Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A.R., Coukos, G., de Gruijl, T.D., Dillman, R.O., Dolstra, H., Dranoff, G., Durrant, L.G., Finke, J.H., Galon, J., Gollob, J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Hakansson, L., Hege, K., Herberman, R.B., Hodi, F.S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E.M., Janetzki, S., June, C.H., Kalinski, P., Kaufmann, H.L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S.N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H.I., Lotze, M.T., Di Maio, M., Marschner, J.P., Mastrangelo, M.J., Masucci, G., Melero, I., Nelief, C., Murphy, W.J., Nelson, B., Nicolini, A., Nishimura, M.I., Odunsi, K., Ohashi, P.S., O'Donnell-Tormey, J., Old, L.J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P.J., Salem, M.L., Scheper, R.J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P.T., Tahara, H., Tian, Z., van der Burg, S.H., von Hoegen, P., Wang, E., Welters, M.J., Winter, H., Withington, T., Wolchok, J.D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F.M., Gajewski, T.F., Wigginton, J.M., Disis, M.L.A., Fox, BA, Schendel, D.J., Butterfield, L.H., Aamdal, S., Allison, J.P., Ascierto, P.A., Atkins, M.B., Bartunkova, J., Bergmann, L., Berinstein, N., Bonorino, C.C., Borden, E., Bramson, J.L., Britten, C.M., Cao, X., Carson, W.E., Chang, A.E., Characiejus, D., Choudhury, A.R., Coukos, G., de Gruijl, T.D., Dillman, R.O., Dolstra, H., Dranoff, G., Durrant, L.G., Finke, J.H., Galon, J., Gollob, J.A., Gouttefangeas, C., Grizzi, F., Guida, M., Hakansson, L., Hege, K., Herberman, R.B., Hodi, F.S., Hoos, A., Huber, C., Hwu, P., Imai, K., Jaffee, E.M., Janetzki, S., June, C.H., Kalinski, P., Kaufmann, H.L., Kawakami, K., Kawakami, Y., Keilholtz, U., Khleif, S.N., Kiessling, R., Kotlan, B., Kroemer, G., Lapointe, R., Levitsky, H.I., Lotze, M.T., Di Maio, M., Marschner, J.P., Mastrangelo, M.J., Masucci, G., Melero, I., Nelief, C., Murphy, W.J., Nelson, B., Nicolini, A., Nishimura, M.I., Odunsi, K., Ohashi, P.S., O'Donnell-Tormey, J., Old, L.J., Ottensmeier, C., Papamichail, M., Parmiani, G., Pawelec, G., Proietti, E., Qin, S., Rees, R., Ribas, A., Ridolfi, R., Ritter, G., Rivoltini, L., Romero, P.J., Salem, M.L., Scheper, R.J., Seliger, B., Sharma, P., Shiku, H., Singh-Jasuja, H., Song, W., Straten, P.T., Tahara, H., Tian, Z., van der Burg, S.H., von Hoegen, P., Wang, E., Welters, M.J., Winter, H., Withington, T., Wolchok, J.D., Xiao, W., Zitvogel, L., Zwierzina, H., Marincola, F.M., Gajewski, T.F., Wigginton, J.M., and Disis, M.L.A.

Abstract

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. © 2011 Fox et al; licensee BioMed Central Ltd.

Published
2011
Full Text
View/download PDF

35. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

Author

Ebers, GC, Rice, G, Lesaux, J, Paty, D, Oger, J, Li, DKB, Beall, S, Devonshire, V, Hashimoto, S, Hooge, J, Kastrukoff, L, Krieger, C, Mezei, M, Seland, P, Vorobeychi, G, Morrison, W, Nelson, J, Freedman, MS, Chrisie, S, Nelson, R, Rabinovitch, H, Freedman, C, Hartung, HP, Rieckmann, P, Archelos, J, Jung, S, Weilbach, F, Flachenecke, P, Sauer, J, Hommes, O, Jongen, P, Brouwer, S, McLeod, J, Pollard, J, Ng, R, Sandberg-Wollheim, M, Kallen, K, Nilsson, P, Ekberg, R, Lundgren, A, Jadback, G, Wikstrom, J, Multanen, J, Valjakka, M, Carton, H, Lissoir, F, Declerq, I, Vieren, M, Peeters, E, Dubois, B, Dekeersmaeker, E, Van Herle, A, Hughes, RAC, Sharrack, B, Soudain, S, Panelius, M, Eralinna, J, Soilu-Hanninen, M, Murto, S, Medaer, R, Broeckx, J, Vanroose, E, Bogaers, A, Blumhardt, LD, Edwards, S, Liu, C, Orpe, V, Barnes, D, Schwartz, M, Stoy, N, Harraghy, C, Bertelsmann, F, Uitdehaag, B, Nasseri, K, Chofflon, M, Roth, S, Kappos, L, Huber, S, Bellaiche, Y, Senn, C, King, J, Jubert, J, Whitten, S, Newsom-Davis, JM, Palace, J, Lee, M, Evangelou, N, Pinto, A, Cavey, A, Sindic, CJM, Monteyne, P, Verougstraete, D, Van Doorn, PA, Moll, W, Visser, L, Willems, M, Martina, I, Buljevac, D, Loman, L, Bates, D, Pandit, D, Irving, J, Rhodes, B, Riddehough, A, Zhao, GJ, Wang, X, Cheng, Y, Ammoury, N, Dupont, F, Galazka, A, Hyde, R, Olson, M, Pernin, MO, Abdul-Ahad, AK, Noseworthy, J, Borden, E, O'Brien, P, Wolinsky, J, and Grp, PRISMSS

Abstract

BACKGROUND: Previous trials of interferon beta in multiple sclerosis (MS) have shown efficacy, but the degree of clinical benefit remains uncertain, and the optimum dose is not known. We undertook a double-blind, placebo-controlled study in relapsing/remitting MS to investigate the effects of subcutaneous interferon beta-1a. METHODS: 560 patients with Kurtzke expanded disability status scale (EDSS) scores of 0-5.0, from 22 centres in nine countries, were randomly assigned subcutaneous recombinant interferon beta-1a 22 microg (n=189), or 44 microg (n=184), or placebo (n=187) three times a week for 2 years. Neurological examinations were done every 3 months. All patients had MRI twice yearly and 205 had monthly scans in the first 9 months of treatment. Analysis was by intention to treat. FINDINGS: Clinical data on 533 (95%) patients were available at 2 years. The relapse rate was significantly lower at 1 and 2 years with both doses of interferon beta-1a than with placebo (mean number per patient 1.82 for 22 microg group, 1.73 for 44 microg group vs 2.56 for placebo group: risk reductions 27% [95% CI 14-39] and 33 [21-44]). Time to first relapse was prolonged by 3 and 5 months in the 22 microg and 44 microg groups respectively, and the proportion of relapse-free patients was significantly increased (p

Published
1998

36. ANGIOGENESIS AND INVASION

Author

Hu, Y.-L., primary, De Lay, M., additional, Rose, S. D., additional, Carbonell, W. S., additional, Aghi, M. K., additional, Hu, Y.-L., additional, Paquette, J., additional, Tokuyasu, T., additional, Tsao, S., additional, Chaumeil, M., additional, Ronen, S., additional, Matlaf, L. A., additional, Soroceanu, L., additional, Cobbs, C., additional, Matlaf, L., additional, Harkins, L., additional, Garzon-Muvdi, T., additional, Rhys, C. a., additional, Smith, C., additional, Kim, D.-H., additional, Kone, L., additional, Farber, H., additional, An, S., additional, Levchenko, A., additional, Quinones-Hinojosa, A., additional, Lemke, D., additional, Pfenning, P.-N., additional, Sahm, F., additional, Klein, A.-C., additional, Kempf, T., additional, Schnolzer, M., additional, Platten, M., additional, Wick, W., additional, Smith, S. J., additional, Rahman, R., additional, Rahman, C., additional, Barrow, J., additional, Macarthur, D., additional, Rose, F., additional, Grundy, R. G., additional, Kaley, T. J., additional, Huse, J., additional, Karimi, S., additional, Rosenblum, M., additional, Omuro, A., additional, DeAngelis, L. M., additional, de Groot, J. F., additional, Kong, L.-Y., additional, Wei, J., additional, Wang, T., additional, Piao, Y., additional, Liang, J., additional, Fuller, G. N., additional, Qiao, W., additional, Heimberger, A. B., additional, Jhaveri, N., additional, Cho, H., additional, Torres, S., additional, Wang, W., additional, Schonthal, A., additional, Petasis, N., additional, Louie, S. G., additional, Hofman, F., additional, Chen, T. C., additional, Yamada, R., additional, Sumual, S., additional, Buljan, V., additional, Bennett, M. R., additional, McDonald, K. L., additional, Weiler, M., additional, Thiepold, A.-L., additional, Jestaedt, L., additional, Gronych, J., additional, Dittmann, L. M., additional, Jugold, M., additional, Kosch, M., additional, Combs, S. E., additional, von Deimling, A., additional, Weller, M., additional, Bendszus, M., additional, Kwiatkowska, A., additional, Paulino, V., additional, Tran, N. L., additional, Symons, M., additional, Stockham, A. L., additional, Borden, E., additional, Peereboom, D., additional, Hu, Y., additional, Chaturbedi, A., additional, Hamamura, M., additional, Mark, E., additional, Zhou, Y.-H., additional, Abbadi, S., additional, Guerrero-Cazares, H., additional, Pistollato, F., additional, Smith, C. L., additional, Ruff, W., additional, Puppa, A. D., additional, Basso, G., additional, Monje, M., additional, Freret, M. E., additional, Masek, M., additional, Fisher, P. G., additional, Haddix, T., additional, Vogel, H., additional, Kijima, N., additional, Hosen, N., additional, Kagawa, N., additional, Hashimoto, N., additional, Fujimoto, Y., additional, Kinoshita, M., additional, Sugiyama, H., additional, Yoshimine, T., additional, Anneke, N., additional, Bob, H., additional, Pieter, W., additional, Arend, H., additional, William, L., additional, Eoli, M., additional, Calleri, A., additional, Cuppini, L., additional, Anghileri, E., additional, Pellegatta, S., additional, Prodi, E., additional, Bruzzone, M. G., additional, Bertolini, F., additional, Finocchiaro, G., additional, Zhu, D., additional, Hunter, S. B., additional, Vertino, P. M., additional, Van Meir, E. G., additional, Cork, S. M., additional, Kaur, B., additional, Cooper, L., additional, Saltz, J. H., additional, Sandberg, E. M., additional, Burrell, K., additional, Hill, R., additional, Zadeh, G., additional, Parker, J. J., additional, Dionne, K., additional, Massarwa, R., additional, Klaassen, M., additional, Niswander, L., additional, Kleinschmidt-DeMasters, B. K., additional, Waziri, A., additional, Jalali, S., additional, Wataya, T., additional, Salehi, F., additional, Croul, S., additional, Gentili, F., additional, Foltz, W., additional, Lee, J.-I., additional, Agnihorti, S., additional, Menard, C., additional, Chung, C., additional, Schonthal, A. H., additional, Hofman, F. M., additional, Elena, P., additional, Faivre, G., additional, Demopoulos, A., additional, Taillibert, S., additional, Kirsch, M., additional, Martin, K. D., additional, Bertram, A., additional, uckermann, O., additional, Leipnitz, E., additional, Weigel, P., additional, Temme, A., additional, Schackert, G., additional, Geiger, K., additional, Gerstner, E., additional, Jennings, D., additional, Chi, A. S., additional, Plotkin, S., additional, Kwon, S. J., additional, Pinho, M., additional, Polaskova, P., additional, Batchelor, T. T., additional, Sorensen, A. G., additional, Hossain, M. B., additional, Gururaj, A. E., additional, Cortes-Santiago, N., additional, Gabrusiewicz, K., additional, Yung, W. K. A., additional, Fueyo, J., additional, Gomez-Manzano, C., additional, Gil, O. D., additional, Noticewala, S., additional, Ivkovic, S., additional, Esencay, M., additional, Zagzagg, D., additional, Rosenfeld, S., additional, Bruce, J. N., additional, Canoll, P., additional, Chang, J. H., additional, Seol, H. J., additional, Weeks, A., additional, Smith, C. A., additional, Rutka, J. T., additional, Georges, J., additional, Samuelson, G., additional, Misra, A., additional, Joy, A., additional, Huang, Y., additional, McQuilkin, M., additional, Yoshihiro, A., additional, Carpenter, D., additional, Butler, L., additional, Feuerstein, B., additional, Murphy, S. F., additional, Vaghaiwalla, T., additional, Wotoczek-Obadia, M., additional, Albright, R., additional, Mack, D., additional, Lawn, S., additional, Henderson, F., additional, Jung, M., additional, Dakshanamurthy, S., additional, Brown, M., additional, Forsyth, P., additional, Brem, S., additional, Sadr, M. S., additional, Maret, D., additional, Sadr, E. S., additional, Siu, V., additional, Alshami, J., additional, Trinh, G., additional, Denault, J.-S., additional, Faury, D., additional, Jabado, N., additional, Nantel, A., additional, and Del Maestro, R., additional

Published
2011
Full Text
View/download PDF

49. Phase IA/IB Evaluation of Mammalian Cell-derived Glycosylated Recombinant Human Interleukin (SIGOSIX) before and after Cytotoxic Chemotherapy

Author

RITCH, P. S., primary, KEEVER, C., additional, SCHILLER, J., additional, RIVKIN, S., additional, WITT, P. L., additional, GROSSBERG, S. E., additional, TRUITT, R. L., additional, BURRIS, H., additional, HOFF, D. D., additional, VAICKUS, L., additional, DRECHSLER, D., additional, BORDEN, E. C., additional, GALAZKA, A., additional, BREITMEYER, J. B., additional, and ABDUL-AHAD, A., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results